Your browser doesn't support javascript.
loading
Generation of CD34+CD43+ Hematopoietic Progenitors to Induce Thymocytes from Human Pluripotent Stem Cells.
Flippe, Léa; Gaignerie, Anne; Sérazin, Céline; Baron, Olivier; Saulquin, Xavier; Anegon, Ignacio; David, Laurent; Guillonneau, Carole.
Afiliação
  • Flippe L; Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
  • Gaignerie A; Nantes Université, CHU Nantes, Inserm, CNRS, BioCore, 44035 Nantes, France.
  • Sérazin C; Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
  • Baron O; Département de Chirurgie Cardiaque Pédiatrique, CHU Nantes, 44093 Nantes, France.
  • Saulquin X; Nantes Université, Inserm, CNRS, CRCI2NA, 44035 Nantes, France.
  • Anegon I; Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
  • David L; Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.
  • Guillonneau C; Nantes Université, CHU Nantes, Inserm, CNRS, BioCore, 44035 Nantes, France.
Cells ; 11(24)2022 12 14.
Article em En | MEDLINE | ID: mdl-36552810
Immunotherapy using primary T cells has revolutionized medical care in some pathologies in recent years, but limitations associated to challenging cell genome edition, insufficient cell number production, the use of only autologous cells, and the lack of product standardization have limited its clinical use. The alternative use of T cells generated in vitro from human pluripotent stem cells (hPSCs) offers great advantages by providing a self-renewing source of T cells that can be readily genetically modified and facilitate the use of standardized universal off-the-shelf allogeneic cell products and rapid clinical access. However, despite their potential, a better understanding of the feasibility and functionality of T cells differentiated from hPSCs is necessary before moving into clinical settings. In this study, we generated human-induced pluripotent stem cells from T cells (T-iPSCs), allowing for the preservation of already recombined TCR, with the same properties as human embryonic stem cells (hESCs). Based on these cells, we differentiated, with high efficiency, hematopoietic progenitor stem cells (HPSCs) capable of self-renewal and differentiation into any cell blood type, in addition to DN3a thymic progenitors from several T-iPSC lines. In order to better comprehend the differentiation, we analyzed the transcriptomic profiles of the different cell types and demonstrated that HPSCs differentiated from hiPSCs had very similar profiles to cord blood hematopoietic stem cells (HSCs). Furthermore, differentiated T-cell progenitors had a similar profile to thymocytes at the DN3a stage of thymic lymphopoiesis. Therefore, utilizing this approach, we were able to regenerate precursors of therapeutic human T cells in order to potentially treat a wide range of diseases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes / Células-Tronco Pluripotentes Induzidas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes / Células-Tronco Pluripotentes Induzidas Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article